Filtered By:
Nutrition: Vitamins

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 3481 results found since Jan 2013.

Does Sex Affect Anticoagulant Use for Stroke Prevention in Nonvalvular Atrial Fibrillation?: The Prospective Global Anticoagulant Registry in the FIELD-Atrial Fibrillation Original Articles
Conclusions— These contemporary global data show that anticoagulant use for stroke prevention is no different in men and women with nonvalvular AF. Thromboprophylaxis was, however, suboptimal in substantial proportions of men and women, with underuse in those at moderate-to-high risk of stroke and overuse in those at low risk. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362.
Source: Circulation: Cardiovascular Quality and Outcomes - March 5, 2015 Category: Cardiology Authors: Lip, G. Y. H., Rushton-Smith, S. K., Goldhaber, S. Z., Fitzmaurice, D. A., Mantovani, L. G., Goto, S., Haas, S., Bassand, J.-P., Camm, A. J., Ambrosio, G., Jansky, P., Al Mahmeed, W., Oh, S., van Eickels, M., Raatikainen, P., Steffel, J., Oto, A., Kayani, Tags: Health policy and outcome research, Coumarins, Other anticoagulants, Arrhythmias, clinical electrophysiology, drugs Original Articles Source Type: research

Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation
Stroke is a leading cause of morbidity and mortality worldwide. Atrial fibrillation (AF) is an independent risk factor for stroke, increasing the risk five-fold. Strokes in patients with AF are more likely than other embolic strokes to be fatal or cause severe disability and are associated with higher healthcare costs, but they are also preventable. Current guidelines recommend that all patients with AF who are at risk of stroke should receive anticoagulation. However, despite this guidance, registry data indicate that anticoagulation is still widely underused. With a focus on the 2012 update of the European Society of Car...
Source: Europace - June 26, 2015 Category: Cardiology Authors: Camm, A. J., Pinto, F. J., Hankey, G. J., Andreotti, F., Hobbs, F. D. R., on behalf of the Writing Committee of the Action for Stroke Prevention alliance, on behalf of the Writing Committee of the Action for Stroke Prevention alliance, John Camm, Pinto, H Tags: REVIEW Source Type: research

Discrepancy between guidelines for stroke prevention in atrial fibrillation and practice patterns in primary care. The nationwide French AFIGP survey.
CONCLUSIONS: In this large French study, approximately 45% of thromboembolic high-risk patients were either not treated or inadequately treated. Better compliance with evidence-based guidelines is needed to reduce the burden of stroke in the AF population. PMID: 26113478 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - June 22, 2015 Category: Cardiology Authors: Sabouret P, Bricard M, Hermann MA, Cotté FE, Deret-Bixio L, Rushton-Smith S Tags: Arch Cardiovasc Dis Source Type: research

Serum Vitamin D Status as a Predictor of Prognosis in Patients with Acute Ischemic Stroke
Background: Low 25-hydroxyvitamin D (25(OH)D) concentrations have been shown to predict risk of cardiovascular disease and all-cause mortality. Although the prevalence of 25(OH)D deficiency is high in patients with acute stroke, the prognostic value of 25(OH)D in stroke has not been clearly established. The purpose of this study was to determine whether the baseline serum 25(OH)D level was associated with the functional outcome in patients with acute ischemic stroke. Methods: From June 2011 to January 2014, consecutive patients with acute ischemic stroke within 7 days of symptom onset were enrolled in this study from a pro...
Source: Cerebrovascular Diseases - July 11, 2015 Category: Neurology Source Type: research

Patients with atrial fibrillation and low risk of stroke - do they really need anticoagulation?
Authors: Trusz-Gluza M, Filipecki A, Urbańczyk-Świć D Abstract Atrial fibrillation (AF) significantly increases risk of thromboembolic events, in particular the risk of stroke. Anticoagulation therapy reduces this risk and the treatment should be lifelong. However, the risk in patients with non-valvular AF is not equally distributed. There are patients at low risk. Assessment of the thromboembolic risk according to guidelines is mandatory, most frequently CHA2DS2-VASc scheme is used. In the large group with the CHA2DS2-VASc-0 (females 1) the annual risk of stroke was 0.49%, ischemic stroke 0.43%, on the other si...
Source: Polskie Archiwum Medycyny Wewnetrznej - August 28, 2015 Category: Internal Medicine Tags: Pol Arch Med Wewn Source Type: research

Abstract 203: Preventing Stroke in Patients With Atrial Fibrillation: A Review of Published Interventions to Aid Patient Decision Making Session Title: Abstract Poster Session II
Conclusion: Interventions designed to aid patient decision making around stroke prevention in AF improved a selection of patient-centered outcomes. Given the availability of multiple NOACs and an implantable device for stroke prevention in AF, there is a need to develop and evaluate new patient decision support tools.
Source: Circulation: Cardiovascular Quality and Outcomes - February 26, 2016 Category: Cardiology Authors: ONeill, E. S., Grande, S. W., Elwyn, G., Coylewright, M. Tags: Session Title: Abstract Poster Session II Source Type: research

Spotlight on unmet needs in stroke prevention: The PIONEER AF-PCI, NAVIGATE ESUS and GALILEO trials.
This article focuses on three randomised controlled trials (RCTs) that are investigating the utility of rivaroxaban, a direct, oral, factor Xa inhibitor, in additional areas of stroke prevention where data for anticoagulants are lacking: oPen-label, randomized, controlled, multicentre study explorIng twO treatmeNt stratEgiEs of Rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment (PIONEER AF-PCI); New Approach riVaroxoban Inhibition of factor Xa in a Global trial vs Aspirin to prevenT Embolism in Embolic Stroke of Undetermined Source (NAVIGATE ESUS); and Global study comparing a rivAroxaban-based antithrombo...
Source: Thrombosis and Haemostasis - September 13, 2016 Category: Hematology Authors: Hemmrich M, Peterson ED, Thomitzek K, Weitz JI Tags: Thromb Haemost Source Type: research

Serum 25 ‐hydroxyvitamin D deficiency predicts poor outcome amongst acute ischaemic stroke patients with low high density lipoprotein cholesterol
ConclusionsVitamin D deficiency may be merely an independent risk factor of poor prognosis in ischaemic stroke patients with low HDLC level.
Source: European Journal of Neurology - September 18, 2016 Category: Neurology Authors: T. Xu, C. Zhong, Y. Peng, C. ‐S. Chen, J. Wang, Z. Ju, Q. Li, D. Geng, Y. Sun, D. Zhang, Y. Zhang, J. Chen, T. Xu, Y. Zhang, J. He Tags: Original Article Source Type: research

Association between hyperhomocysteinemia and stroke with atherosclerosis and small artery occlusion depends on homocysteine metabolism-related vitamin levels in Chinese patients with normal renal function
This study was conducted to investigate the role of different homocysteine metabolism-related vitamin (HMRV) levels in the correlation between hyperhomocysteinemia (HHCY) and ischemic stroke (IS) subtypes. Three hundred and forty-eight IS patients manifesting different vascular subtypes were subclassified on the basis of HMRV deficiencies. Correlation between HHCY and IS subtypes was investigated in all the subgroups. In this study, HHCY was significantly correlated with the IS subtypes in large artery atherosclerosis (OR 1.126, 95%CI: 1.051  ~ 1.206,P = 0.001) and small artery occlusion (OR 1.105, 95%CI: 1.023 ~ 1.1...
Source: Metabolic Brain Disease - March 5, 2017 Category: Neurology Source Type: research

Factors associated with non –vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice, up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists, and had higher socioeconomic status. Trial registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 25, 2017 Category: Cardiology Source Type: research

Serum 25-hydroxyvitamin D deficiency predicts long-term poor prognosis among ischemic stroke patients without hyperglycaemia
Conclusion Serum 25(OH)D deficiency may be merely an independent risk factor of 1-year poor prognosis in ischemic stroke patients without hyperglycemia. Future studies about improving long-term prognosis of ischemic stroke by vitamin D supplementation could be first applied to these patients.
Source: Clinica Chimica Acta - May 22, 2017 Category: Laboratory Medicine Source Type: research

Pharmacological and Non-pharmacological Treatments for Stroke Prevention in Patients with Atrial Fibrillation
AbstractAtrial fibrillation (AF) is associated with significant risk of stroke and other thromboembolic events, which can be effectively prevented using oral anticoagulation (OAC) with either vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, or edoxaban. Until recently, VKAs were the only available means for OAC treatment. NOACs had similar efficacy and were safer than or as safe as warfarin with respect to reduced rates of hemorrhagic stroke or other intracranial bleeding in the respective pivotal randomized clinical trials (RCTs) of stroke prevention in non-valvular AF...
Source: Advances in Therapy - September 27, 2017 Category: Drugs & Pharmacology Source Type: research

The risk of ischaemic stroke in primary APS patients: a prospective study
ConclusionsPatients with PAPS, including young patients, have a high risk of recurrent thrombosis despite anticoagulation treatment. A careful risk assessment is mandatory to identify patients at risk for recurrence.This article is protected by copyright. All rights reserved.
Source: European Journal of Neurology - October 30, 2017 Category: Neurology Authors: Massimo Radin, Karen Schreiber, Irene Cecchi, Dario Roccatello, Maria Jos é Cuadrado, Savino Sciascia Tags: Original Article Source Type: research

The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study
ConclusionsPatients with PAPS, including young patients, have a high risk of recurrent thrombosis despite anticoagulation treatment. A careful risk assessment is mandatory to identify patients at risk for recurrence.
Source: European Journal of Neurology - December 2, 2017 Category: Neurology Authors: M. Radin, K. Schreiber, I. Cecchi, D. Roccatello, M. J. Cuadrado, S. Sciascia Tags: Original Article Source Type: research

Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.
CONCLUSION: QD NOACs prevented a significant number of strokes and caused no significant increase in MBs compared to BID NOACs which leads to significant net cost savings for NVAF patients in the US. PMID: 30265159 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - September 29, 2018 Category: Research Tags: Curr Med Res Opin Source Type: research